Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT009 versus PT005, PT008, and open-label Symbicort in moderate to very severe COPD
2016-000154-34Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol fumarate, formoterol fumarate MDI and budesonide in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Started Sep 2016; status: completed.
02
Drugs
budesonide + formoterol fumarateformoterol fumarate MDIbudesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-000154-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000154-34.